Back

Real world data using sacubitril/valsartan in CKD stage 4 and 5 is associated with improved ejection fraction and may have renoprotective effects.

12 May 2024 (13:00 - 13:45)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 9 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Mark Sweeney

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail
Real-life management of heart failure: evaluation of medication optimisation in different phenotypes.
Miss H. Hauksdottir (Reykjavik, IS)
Abstract Slides Video
Presentation thumbnail
The effect of an incentive billing code on heart failure management in primary care: a population-based study
Doctor S. Zhou (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
A novel dual-action insulin secreting and natriuretic peptide, CRRL 101, a potential therapy for diabetic cardiomyopathy
Doctor I. Isaia (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Evaluation of the effects of the Sodium-glucose cotransporter 2 inhibitors and sacubitril/valsartan combined therapy in patients with HFrEF: echocardiographic study.
Doctor I. Fumarulo (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Persistence of autoantibodies directed against the beta-1-adrenoceptor in patients with heart failure after treatment with BC 007 (Rovunaptabin). Results of a phase IIa study.
Associate Professor M. Zdravkovic (Belgrade, RS)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - treatment 9

The Event

Event poster

Heart Failure 2024

12 May 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of sacubitril/valsartan in the management of heart failure with reduced ejection fraction and chronic kidney disease: a systematic review and meta-analysis
thumbnail
Congress Presentation
Effects of sacubitril/valsartan in patients with heart failure with reduced ejection fraction and an eGFR below 30 ml/min/1.73 m2
thumbnail
Congress Presentation
Atrial fibrillation in patients with heart failure with reduced ejection fraction: a real-world analysis on renal function and left ventricular ejection fraction changes with outcome implications

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources